[at noodls] – Group net sales up 2% in constant currencies[1] (cc) in fourth quarter despite patent expirations; flat (cc) over full year Fourth quarter net sales reached USD 14.8 billion (0%, +2% cc); full year net … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, […]
[at noodls] – CHMP endorsed the use of Ilaris in patients with acute gouty arthritis, who suffer frequent attacks and for whom current treatments are unsuitable or ineffective Ilaris, the only approved fully human monoclonal … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, click here […]
[at noodls] – Novartis advances goals set as part of a coordinated, international effort to eliminate or control 10 neglected tropical diseases (NTDs) Over 500 facilities in Tanzania now use SMS for Life to track the … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, click […]
[at noodls] – Phase III results show that Bexsero induced a robust immune response when administered concomitantly with routine vaccines, and also as a booster dose[1] Data confirm Bexsero’s acceptable safety and tolerability … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, click here to view […]
[at noodls] – More than 40% of TSC patients on everolimus had their kidney tumor volume reduced by at least half with no tumor progression[1] Separate data show 35% of TSC patients treated with everolimus had their … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, […]
[at noodls] – Exjade is the first oral treatment approved in the EU for chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes Pivotal placebo-controlled study data show Exjade … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, click here to view […]
[at noodls] – As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing’s disease[1] In the Phase III trial, most patients experienced … moreView todays social media effects on NVSView the latest stocks trending across Twitter. Click to view dashboardSee who Novartis is hiring next, click here to view […]
